ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.
Click here to answer this week's poll.
This week's edition of the Mainstream Patient features stories about filler fatigue in 2023, the difference between RF microneedling and traditional microneedling, IPL hair removal devices, and more.
Researchers said laser and intense pulse light-induced vitiligo lacks consensus in prevention and safety measures.
Now that we’re 4 months into 2023, many New Year’s resolutions have ended up in the rearview mirror.
The study suggests that treatments for allergic reactions could help decrease the risk of having joint problems.
A new survey found that the demographics are not following safe sun habits and have low skin cancer awareness.
ADX‑629 also is being evaluated in Phase 2 clinical trials for the treatment of chronic cough, idiopathic nephrotic syndrome, and Sjögren-Larsson Syndrome.
The gut-brain-skin axis is more important to overall health than previously understood, and prebiotics and probiotics play a large role in the benefits.
Click here to answer this poll related to Rosacea Awareness Month.
Researchers said the drug was also well-tolerated in patients.
The skin microbiome varies from person to person based on sex, age, body location, antimicrobial peptide presence, and immune function.
The study was the first to examine the fruit's properties as a wound-healing agent and skin protectant.
Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care.
The association between psoriasis and dyslipidemia is well established, although pathogenic pathways are not yet understood.
Verrica Pharmaceuticals is developing a potentially first-in-class oncolytic peptide.
Researchers in a recent study said women are more likely to experience these effects, which can affect internal health.
The PD-1 inhibitor pembrolizumab has proven its efficacy in a number of different cancers.
In this week’s Pointers with Portela, the 208SkinDoc discusses the safety of made-to-fade tattoos.
Researchers said the drug successfully altered C. acnes strains and more in a recent study.
Merck and Eisai discontinued the trial based on recommendations of an independent data monitoring committee.
This will be the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint.
Researchers compiled future research directions and therapeutic and clinical developments in psoriasis.
Patients can achieve reduced excessive underarm sweating after one in-office treatment.
Oral vitamin D supplementation does not appear to have an effect on disease severity for those with low 25-hydroxyvitamin D (25[OH]D) levels.
Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
April is National Rosacea Month. Recent data has indicated a correlation between rosacea and certain cardiovascular, neurologic, endocrine, and gastrointestinal disorders. Steve Daveluy, MD, FAAD, shares insight on that, plus several new and exciting therapies available.
Researchers said several geographic and demographic factors or changes have led to new skin manifestations.
A review of prior research shows that topical beeswax may have several dermatologic benefits.